Clinical trial
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
NCT00026429 · Pharmatech Oncology, Industry · Unknown status
Key facts
| NCT number | NCT00026429 |
|---|---|
| Title | Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma |
| Official title | A Multicenter Phase II Evaluation Of ONTAK (DENILEUKINDIFTITOX) In Patients With Low Or Intermediate Grade-B-Cell Non-Hodgkin's Lymphoma Who Have Been Treated Previously With A Monoclonal Antibody Or Who Are Not Candidates For Monoclonal Antibody Therapy |
| Lead sponsor | Pharmatech Oncology, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Biological |
| Interventions | denileukin diftitox |
| Start date | Jan 1, 2001 |
| First posted | Feb 27, 2004 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: